3692.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 13:38):

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...

Stats
आज की मात्रा	6.48M
औसत मात्रा	5.62M
बाजार मूल्य	103.65B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.0707 ( 2023-09-15 )
Next Dividend	HKD0 ( N/A )
P/E	31.21
ATR14	HKD0.0180 (0.10%)

मात्रा सहसंबंध

लंबा: 0.04 (neutral)

छोटा: -0.52 (weak negative)

Signal:(69.894) Neutral

Hansoh Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Hansoh Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

-0.34
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.58
( weak negative )

-0.18
( neutral )

0.70
( moderate )

Hansoh Pharmaceutical वित्तीय

Annual	2023
राजस्व:	HKD10.10B
सकल लाभ:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2023
राजस्व:	HKD10.10B
सकल लाभ:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2022
राजस्व:	HKD9.38B
सकल लाभ:	HKD8.51B (90.73 %)
EPS:	HKD0.440

FY	2021
राजस्व:	HKD9.94B
सकल लाभ:	HKD9.07B (91.24 %)
EPS:	HKD0.460

Financial Reports:

No articles found.

Hansoh Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0500 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0500 (N/A)	HKD0.141 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Hansoh Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.64 - Stable (32.86%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0771	2021-06-07
Last Dividend	HKD0.0707	2023-09-15
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.576	--
Avg. Dividend % Per Year	0.00%	--
Score	3.76	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.64
Div. Directional Score	8.95	--

Next Divdend (Est)
(2024-09-27)

HKD0.0743 Estimate 11.67 %

Dividend Stability

0.47 Below Average

Dividend Score

3.76

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6083.HK	Ex Dividend Knight	2023-06-12	Semi-Annually	0.00%
1843.HK	Ex Dividend Knight	2023-09-05	Annually	0.00%
0868.HK	Ex Dividend Knight	2023-08-11	Semi-Annually	0.00%
0016.HK	Ex Dividend Knight	2023-11-06	Semi-Annually	0.00%
2633.HK	Ex Dividend Knight	2023-08-15	Semi-Annually	0.00%
1412.HK	Ex Dividend Knight	2023-06-12	Semi-Annually	0.00%
0497.HK	Ex Dividend Junior	2023-08-25	Annually	0.00%
6858.HK	Ex Dividend Knight	2023-09-20	Semi-Annually	0.00%
1962.HK	Ex Dividend Junior	2023-09-11	Annually	0.00%
0992.HK	Ex Dividend Knight	2023-07-26	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.324	1.500	3.51	5.27	[0 - 0.5]
returnOnAssetsTTM	0.0992	1.200	6.69	8.03	[0 - 0.3]
returnOnEquityTTM	0.131	1.500	9.65	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.21	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.02	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.27	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.130	-1.500	7.84	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.160	2.00	9.92	10.00	[0 - 20]
debtEquityRatioTTM	0.166	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.898	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.265	1.000	6.70	6.70	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.295	-1.036	[0.5 - 2]
Total Score				11.25

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	33.03	1.000	6.76	0	[1 - 100]
returnOnEquityTTM	0.131	2.50	9.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.160	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	1.166	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	4.64	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.113	1.000	9.66	0	[0.1 - 0.5]
Total Score				6.64

Hansoh Pharmaceutical

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.